Toripalimab Combined with Targeted Therapy and Chemotherapy Achieves Pathologic Complete Response in the Perioperative Management of Gastric Carcinoma: A Case Report

Toripalimab Combined with Targeted Therapy and Chemotherapy in Gastric Carcinoma

Rui Liu, Xia Wang, Zhi Ji, Ting Deng, Hongli Li, Yanhui Zhang, Yuchong Yang, Shaohua Ge, Le Zhang, Ming Bai, Tao Ning, Yi Ba
Abstract

BACKGROUND

Neoadjuvant or perioperative chemotherapy combined with surgery can reduce postoperative recurrence and improve the long-term survival rate of patients with locally advanced resectable gastric carcinoma. Nivolumab combined with chemotherapy has been recommended by the National Comprehensive Cancer Network guidelines as a first-line therapy for advanced gastric carcinoma/adenocarcinoma of the gastroesophageal junction and serves as the basis for immunotherapy combined with chemotherapy to become a neoadjuvant therapy. Herein, we report a case in which pathologic complete response was achieved by neoadjuvant administration of toripalimab, Herceptin, and docetaxel, oxaliplatin, calcium folinate, and fluorouracil (FLOT) chemotherapy followed by surgery for human epidermal growth factor receptor 2 (HER2)-positive and programmed death-ligand 1 (PD-L1)-positive locally advanced gastric carcinoma. We hope that this case will shed some light on neoadjuvant therapy for gastric carcinoma.

CASE SUMMARY

The patient was diagnosed with locally advanced adenocarcinoma of the cardia. Immunohistochemistry of the baseline tissues suggested that the tissues were HER2-positive (positive result in the retest by fluorescent in situ hybridization) and PD-L1-positive (combined positive score = 1). The patient underwent surgery following a four-cycle neoadjuvant therapy comprising Herceptin, toripalimab, and FLOT chemotherapy. The postoperative pathological findings showed mild atypical hyperplasia of the local glands with chronic mucosal inflammation (proximal stomach), no clear residual tumor (tumor regression grade 0), no lymph node metastasis in the regional lymph nodes, and negative upper and lower cut ends. The levels of tumor markers were reduced to normal levels after re-examination. With good postoperative recovery, the four-cycle preoperative chemotherapy was continued with the same dosage as that previously administered. After the treatment, the patient was monitored
every three months with a follow-up of 12 mo (4 times). As of February 27, 2022, he was in a good condition without disease progression. The clinical trial registration number is E2019401.

CONCLUSION
There are many ongoing studies on neoadjuvant immunotherapy combined with chemotherapy or radiotherapy, however, most of these studies are phase II studies with small cohorts. According to the results of some current studies, these combined regimens have shown promising results in terms of efficacy and safety. However, the clinical efficacy and safety of the neoadjuvant therapies used in these combined regimens need to be confirmed by additional prospective phase III clinical trials, and further exploration of molecular markers for effective populations is required.

**Key Words:** Toripalimab; Targeted therapy; Chemotherapy; Perioperative management; Gastric carcinoma; Case report


**Core Tip:** Herceptin, and FLOT chemotherapy followed by surgery for HER2- and PD-L1-positive locally advanced gastric carcinoma. We hope that this case will shed some light on neoadjuvant therapy for gastric carcinoma.

INTRODUCTION
Gastric carcinoma has a high incidence in China. Surgery might be a radical cure for gastric carcinoma; however, it is limited to only early-stage gastric carcinoma (stage I). The 5-year survival rate of patients with locally advanced gastric carcinoma (late stage)
is 30%-50%\(^1\), even with an extended area of resection and lymph node dissection. Many studies have confirmed that the combination of adjuvant/neoadjuvant chemotherapy/chemoradiotherapy can improve patients’ prognosis, enhance R0 resection rates, reduce distant metastases and recurrence rates, and improve survival rates through tumor downstaging\(^2\)-\(^4\). In the European randomized controlled phase III AIO-FLOT4 trial, resectable gastric carcinoma patients received either the FLOT (docetaxel, oxaliplatin, calcium folinate, and fluorouracil) or ECF (epirubicin, cisplatin, and fluorouracil) regimen before and after surgery. The results showed that the FLOT regimen had better efficacy, higher R0 resection rate, better disease-free survival (DFS), and better overall survival (OS) than the ECF regimen, which laid the foundation for the FLOT regimen to become a new standard perioperative therapy for advanced gastric carcinoma. Therefore, a regimen that combines surgery with neoadjuvant or perioperative chemotherapy has been recommended by the guidelines of the Chinese Society of Clinical Oncology, the European Society for Medical Oncology, and the National Comprehensive Cancer Network (NCCN).

The KEYNOTE-059\(^5\) and ATTRACTION-02\(^6\) trials have suggested that programmed death-1 (PD-1) inhibitors are effective for advanced gastric carcinoma/adenocarcinoma of the gastroesophageal junction. The United States Food and Drug Administration (FDA) and the National Medical Products Administration have approved the indications for pembrolizumab in programmed death-ligand (PD-L1) combined positive score (CPS) ≥1 and nivolumab in the third-line and posterior-line treatment of advanced gastric carcinoma. The CheckMate-649\(^7\) and ATTRACTION-04\(^8\) trials have revealed that nivolumab plus chemotherapy has significantly better efficacy than chemotherapy alone in the first-line treatment of advanced gastric carcinoma/adenocarcinoma. In China, as the first approved immunotherapy targeting PD-1, toripalimab (JS001) induces the endocytosis of PD-1, reduces the expression of PD-1 on the membrane surface, and relieves the immunosuppression of T cells, thereby achieving strong antitumor effects. In 2020, the American Society of Clinical Oncology reported the clinical response and biomarker analysis of first-line toripalimab combined
with standard chemotherapy for solid tumors in a phase II cohort study. The study found that the objective response rate (ORR) was 54.5%, the disease control rate was 84.8%, and the duration of response was 8.3 mo. Moreover, in the randomized controlled phase III KEYNOTE-585 trial, which is currently enrolling patients, therapy-naive patients with locally advanced gastric carcinoma/adenocarcinoma of the gastroesophageal junction in the experimental group will receive pembrolizumab combined with neoadjuvant chemotherapy before surgery and pembrolizumab combined with adjuvant chemotherapy after surgery, whereas those in the control group will receive placebo combined with chemotherapy.

Human epidermal growth factor receptor 2 (HER2), also known as erythroblastic oncogene B2 (ERBB2), is a proto-oncogene encoded by ERBB2 on human chromosome 17. Tyrosine kinase receptor that binds to the membrane is a protein product of this gene. This receptor can promote cell proliferation and inhibit apoptosis, leading to neoplasm formation. HER2 overexpression or amplification are found in 13%-22% of patients with gastric carcinoma or adenocarcinoma of the esophagogastric junction. Immunochemistry (IHC) staining and fluorescent in situ hybridization (FISH) are recommended by the guidelines for the detection of HER2 overexpression in patients with advanced gastric adenocarcinoma. In 2010, trastuzumab was approved by the FDA as a first-line drug in combination chemotherapy for HER2-positive gastric carcinoma. In another study, preliminary results were obtained for combined immunotherapy, trastuzumab, and chemotherapy for gastric carcinoma/esophageal cancer/adenocarcinoma of the esophagogastric junction. The study found that the 6-month progression-free survival (PFS) rate was 75%, the ORR was 91%, the median PFS was 13 mo, and the median OS was 27.3 mo. The above data were better than the previous data for HER2-positive advanced gastric carcinoma.

In this study, we report a case in which pathologic complete response (pCR) was achieved by neoadjuvant toripalimab, Herceptin, and FLOT chemotherapy followed by surgery for HER2- and PD-L1-positive locally advanced gastric carcinoma. We hope to
provide more evidence for neoadjuvant therapies in gastric carcinoma patients by reporting this case.

**CASE PRESENTATION**

*Chief complaints*

A 63-year-old male patient experienced dysphagia, poor appetite, night sweats, and fatigue on July 2, 2020, and sought medical attention at the Hulunbuir People’s Hospital in Inner Mongolia.

*History of present illness*

On July 22, 2020, gastroscopy revealed protuberant lesions in the cardia and fundus; bite biopsy revealed adenocarcinoma of the cardia (Figure 1a); IHC revealed HER-2 (2+, FISH was recommended); in situ hybridization revealed EBER (−); and FISH revealed HER2 positivity (Figure 1c).

*History of past illness*

He has been suffering from hepatitis B virus (HBV) infection for more than 30 years, without history of hypertension, coronary heart disease, diabetes and tuberculosis.

*Personal and family history*

Family history is not applicable.

*Physical examination*

The tissues obtained from the bite biopsy were tested for PD-1, revealing CPS positivity (CPS = 1) (Figure 1b) and TPS negativity.

On July 30, 2020, computed tomography (CT) (Figure 2a) revealed the following findings: 1. Thickened wall of the cardia and adjacent lesser curvature of the stomach, suggestive of carcinoma of the cardia, and invaded fundus and multiple lymph nodes in the hepatogastric ligament region, for which clinical and endoscopic examination
needed to be performed; 2. Multiple cysts in the liver; 3. Cyst of the right kidney; 4. Slightly thickened left adrenal gland, with follow-up visits recommended; 5. Prostatic calcification; 6. Subpleural ground-glass opacity in the right lung and scattered nodules and granules on the pleura of both lungs and under the interlobar pleura, with follow-up visits recommended; and 7. A dot-like compact shadow on the 5th right rib, for which follow-up visits were recommended.

**Laboratory examinations**

On July 22, 2020, gastroscopy revealed protuberant lesions in the cardia and fundus; bite biopsy revealed adenocarcinoma of the cardia; IHC revealed HER-2 (2+, FISH was recommended); in situ hybridization revealed EBER (-); and FISH revealed HER2 positivity. Next-generation sequencing (NGS) revealed TP53 c.329G>C p.Arg110Pro (abundance 33.82%), and ERBB2 copy number amplification (n = 4.5).

**Imaging examinations**

On July 30, 2020, computed tomography (CT) (Figure 2a) revealed the following findings: 1. Thickened wall of the cardia and adjacent lesser curvature of the stomach, suggestive of carcinoma of the cardia, and invaded fundus and multiple lymph nodes in the hepatogastric ligament region, for which clinical and endoscopic examination needed to be performed; 2. Multiple cysts in the liver; 3. Cyst of the right kidney; 4. Slightly thickened left adrenal gland, with follow-up visits recommended; 5. Prostatic calcification; 6. Subpleural ground-glass opacity in the right lung and scattered nodules and granules on the pleura of both lungs and under the interlobar pleura, with follow-up visits recommended; and 7. A dot-like compact shadow on the 5th right rib, for which follow-up visits were recommended.

The imaging findings (CT on October 15, 2020, compared with that on July 30, 2020) after the four cycles of therapy were as follows (Figure 2b): the wall thickness of the cardia and adjacent lesser curvature was less than that before therapy; lymph nodes in the hepatogastric ligament region were reduced in size; and subpleural infiltration in
the right lower lobe was more absorbed. No other significant changes were noted. Upper gastrointestinal tract radiography revealed carcinoma of the cardia.

**FINAL DIAGNOSIS**

1. Thickened wall of the cardia and adjacent lesser curvature of the stomach, suggestive of carcinoma of the cardia, and invaded fundus and multiple lymph nodes in the hepatogastric ligament region, for which clinical and endoscopic examination needed to be performed; 2. Multiple cysts in the liver; 3. Cyst of the right kidney; 4. Slightly thickened left adrenal gland, with follow-up visits recommended; 5. Prostatic calcification; 6. Subpleural ground-glass opacity in the right lung and scattered nodules and granules on the pleura of both lungs and under the interlobar pleura, with follow-up visits recommended; and 7. A dot-like compact shadow on the 5th right rib, for which follow-up visits were recommended.

**TREATMENT**

From July 30, 2020, to September 2020, four-cycle targeted therapy, chemotherapy and immunotherapy were administered. The specific regimen was as follows: trastuzumab: 420 mg in the first cycle and 280 mg in the second cycle; docetaxel: 90 mg, ivd, d1; oxaliplatin: 150 mg, ivd, d1; calcium folinate: 700 mg, ivd, d1; fluorouracil: 4800, civ, 46 h; and toripalimab: 240 mg, ivd, d2; Q2W. Grade I gastrointestinal reaction occurred and improved after symptomatic treatment.

Under general anesthesia, the patient underwent laparoscopic radical D2 gastrectomy for gastric carcinoma on October 23, 2020. Surgical findings revealed a neoplasm at the fundus of the stomach from the cardia, which presented as a 4 × 2-cm ulcer with local serosal invasion. No significantly enlarged lymph nodes were found around the stomach. The lesions presented post-chemotherapy scar-like changes. Multiple small lymph nodes were noted around the stomach, most of which were post-chemotherapy changes. The postoperative pathological findings revealed focal (proximal stomach) mild atypical glandular hyperplasia with chronic mucosal
inflammation, no clear residual tumor (tumor regression grade 0), no lymph node metastasis in the regional lymph nodes, and negative upper and lower cut ends. The grading was as follows: Station 1 0/9, Station 2 0/6, Station 3A 0/12, Station 3B 0/2, Station 4SA soft tissue (−), Station 4SB 0/1 and soft tissue (−), Station 4D 0/2, Station 5 soft tissue (−), Station 6 0/1, Station 7 soft tissue (−), Station 8 soft tissue (−), Station 9 0/4, Station 12A soft tissue (−), Station 19 0/1, and Station 20 0/2. Blood test volume: 5 mL; single cell: 0; circulating tumor microemboli: 0 clusters; total number of circulating tumor cells: 0. A retest of tumor markers showed a return to normal levels.

With good postoperative recovery, the postoperative CT film (performed on November 16, 2020, Figure 2c) was stored, and the four-cycle chemotherapy regimen was continued with the same dosage as that administered previously.

OUTCOME AND FOLLOW-UP

Until February 27, 2022, the patient was examined quarterly for 12 mo (4 times), and he was in a good condition without disease progression.

DISCUSSION

In a study of combined immunotherapy and trastuzumab treatment for HER2-positive gastric carcinoma, 25 patients received immunotherapy and targeted therapy as the initial treatment and chemotherapy in the second cycle, whereas 12 patients received immunotherapy, targeted therapy, and chemotherapy as the initial treatment. In the initial treatment, no significant difference was observed in PFS and 12-month OS between the 25-patient and 12-patient groups. While in our case, the patient did not receive chemotherapy in the initial treatment; more specifically, the patient received Herceptin and toripalimab in the first cycle and chemotherapy in the second cycle. Previous studies have found no difference in survival between groups receiving chemotherapy and groups not receiving chemotherapy in the initial treatment. Our study suggested that, for HER2-positive gastric carcinoma patients, it is worthy to
further evaluate whether the first-line "de-chemotherapy" can be carried out with a large cohort sample.

It is believed that the basis for immunotherapy to benefit HER2-positive patients is that trastuzumab induces antibody-dependent cell-mediated cytotoxicity, improves the presentation of tumor antigens, and paves the way for immunization reaction of tumors\textsuperscript{14}. Clinical data also show that HER2-positive breast cancer has more types of tumor-infiltrating lymphocytes than average, which demonstrates the importance of trastuzumab in immunity induction\textsuperscript{15}. In addition, studies have confirmed that trastuzumab can increase the expression level of PD-L1 in immune cells of patients with breast cancer\textsuperscript{16}. Combined with the encouraging clinical outcome of this patient, it is promising to investigate the systemic immune responses in depth, for instance, the lymphocytes infiltration, the immune markers dynamics, the functional cytokines secretion and so on. Moreover, this patient infected with HBV for many years, which may have an impact on his immune system. Large cohorts are necessary to draw conclusions regarding to this aspect if feasible.

There are many ongoing studies of neoadjuvant immunotherapy combined with chemotherapy or radiotherapy; however, most of these studies are phase II studies with small cohorts. According to some of the results reported thus far, these combined regimens have shown promising efficacy and safety\textsuperscript{17-19} (Table 1). Many studies have shown that chemotherapy can 1) boost the release of damage-associated molecular patterns from tumor cells and improve tumor cell immunogenicity; 2) elevate the level of major histocompatibility complex molecules and enhance tumor antigens presentation\textsuperscript{20}. Additionally, chemotherapy promotes the expression of PD-1/PD-L1 through a variety of signaling pathways. Therefore, in this case, chemotherapy and immunotherapy were applied for the patient before the surgical removal. For gastric carcinoma, first-line immunotherapy combined with chemotherapy is recommended by NCCN guidelines for patients with PD-L1 CPS ≥ 5. However, the CheckMate 649 study\textsuperscript{7} suggested that nivolumab combined with chemotherapy improves the OS and DFS of all patients, including those with CPS ≥ 5 and CPS ≥ 1. In line with this, our patient’s
IHC results revealed PD-L1 with CPS = 1. More prospective cohort studies are needed to determine the selection of biomarkers in neoadjuvant therapies involving immunotherapy and chemotherapy.

Apart from above aspects, tumor protein p53 (TP53) is a crucial tumor suppressor gene, which mutation occurs at an incidence of approximately 45% in gastric carcinoma\textsuperscript{21}. The efficacy of immunotherapy varies with the TP53 mutation. According to the retrospective meta-analysis mentioned above, TP53 mutation was negatively correlated with the patients’ OS with either colon cancer or gastric carcinoma who received immunotherapy but was positively correlated with the efficacy of immunotherapy for lung cancer\textsuperscript{21}. In this study, TP53 c.329G>C p.Arg110Pro mutation was detected using NGS in the baseline tissues of the patient. Therefore, additional prospective cohort studies are required to conclude and explore the correlation between TP53 mutation and the efficacy of immunotherapy for gastric carcinoma.

Here, we demonstrated a case study that the patient was HER2-positive, with locally advanced gastric carcinoma, and there was scope for resection; therefore, a regimen composed of Herceptin, chemotherapy, and immunotherapy was carefully selected to achieve higher efficacy and better surgical resection. The patient was administered the perioperative regimen comprising Herceptin, FLOT, and toripalimab. The postoperative pathological findings revealed that this regimen led to complete tumor response and the levels of tumor biomarkers returned to normal. Furthermore, no circulating tumor cell was detected and no significant immune-related adverse effects was noted, demonstrating that this regimen had sufficient efficacy and safety. The four-cycle chemotherapy was continued postoperatively and completed in the patient, in line with the principle of “effective treatment should be continued if the symptoms are relieved”. This patient is currently in the quarterly follow-up period. A previous study suggested that the ability to achieve postoperative pCR in patients with neoadjuvant therapy is positively correlated with longer durations of survival\textsuperscript{22}. Thus far, all tumors have been removed from this patient using this regimen, and we hope that this regimen will lead to long-time survival benefits.
CONCLUSION

Here, we demonstrated a case study that the patient was HER2-positive, with locally advanced gastric carcinoma, and there was scope for resection; therefore, a regimen composed of Herceptin, chemotherapy, and immunotherapy was carefully selected to achieve higher efficacy and better surgical resection. The patient was administered the perioperative regimen comprising Herceptin, FLOT, and toripalimab. The postoperative pathological findings revealed that this regimen led to complete tumor response and the levels of tumor biomarkers returned to normal. Furthermore, no circulating tumor cell was detected and no significant immune-related adverse effects was noted, demonstrating that this regimen had sufficient efficacy and safety. The four-cycle chemotherapy was continued postoperatively and completed in the patient, in line with the principle of “effective treatment should be continued if the symptoms are relieved”. This patient is currently in the quarterly follow-up period. A previous study suggested that the ability to achieve postoperative pCR in patients with neoadjuvant therapy is positively correlated with longer durations of survival. Thus far, all tumors have been removed from this patient using this regimen, and we hope that this regimen will lead to long-time survival benefits.
<table>
<thead>
<tr>
<th>#</th>
<th>Source</th>
<th>Words</th>
<th>Similarity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>consultqd.clevelandclinic.org</td>
<td>19</td>
<td>1%</td>
</tr>
<tr>
<td>2</td>
<td>cyberleninka.org</td>
<td>17</td>
<td>1%</td>
</tr>
<tr>
<td>3</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>14</td>
<td>&lt; 1%</td>
</tr>
</tbody>
</table>

Exclude quotes: ON
Exclude bibliography: ON
Exclude matches: < 12 words